Special Issue "Cell Death in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 November 2019) | Viewed by 31833
Interests: Colorectal cancer; breast cancer; tumor immunology; neutrophils; macrophages; apoptosis; efferocytosis
Cancer development is often characterized by the deregulation of normal growth and decreased ability to eliminate abnormal cells. The escape of cancer cells from death enables their survival under adverse conditions, leading to aberrant growth. In spite of this resilience, pathologists observe individual disintegrated dead tumor cells in almost all cancer tissues, suggesting a constant release of pro-inflammatory damage associated molecular patterns (DAMPs). The initial type of cell death pathway responsible for this effect may differ between cancers. To escape the elimination by a consequently activated immune system, cancer cells establish an immunosuppressive microenvironment.
Chemotherapies, radiotherapies, and many targeted therapies aim to overcome the anti-apoptotic capacity of tumor cells. However, increasing evidence indicates that these therapies can also induce other types of cell death including necroptosis, ferroptosis, pyroptosis, autophagy-dependent, and immunogenic cell death—each with a distinct underlying molecular mechanism. Of note, autophagy may have other effects on tumor cell growth. Immunomodulatory therapies such as immune checkpoint inhibitors help to release the break on the immune system. These are very successful in specific cancers, but only patients with highly immune cell infiltrated tumors profit from the treatment. Ongoing clinical trials explore the possibilities of increasing the response rate by combining immune checkpoint inhibitors with cell death-inducing therapies. However, recent research indicates that the immunostimulating effect differs between the various cell death pathways, which might affect the success of the treatment strategy.
This Special Issue will review the complexity of cell death pathways in cancer and highlight the role of novel pathways.
Dr. Rudolf Oehler
Prof. Ronit Pinkas-Kramarski
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- regulated cell death
- immunogenicity of cell death